Scholars Central

Case reportPublished 2017

Long-Term Complete Remission of Refractory Primary Cutaneous Anaplastic Large T Cell Lymphoma Treated with Brentuximab Vedotin: A Case Report

Authors: Loseto G, Ciavarella S, Scattone A, Calabrese A, Quinto AM, Guarini A

Cancer Science & Therapy

Volume 9 · Issue 6 · Pages 503–504

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Based on early results from a single phase III trial, Brentuximab Vedotin (BV), a drug-conjugated anti-CD30 monoclonal antibody, is changing the treatment strategy, especially for relapsed/refractory cutaneous anaplastic large cell lymphomas (cALCL) patients with limited therapeutic options. However, despite high response rates registered in this setting, follow-up data about duration of response and long-term toxicity profile are still lacking. Here, we report a case of refractory, advanced stage cALCL in a 78-year old patient with poor prognosis, which showed a dramatic, long-lasting response even to reduced doses of BV as salvage treatment.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Cancer Science & Therapy.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalCancer Science & Therapy
  • SubjectOncology & Cancer
  • BylineArticles whose byline prints “Loseto G”
  • BylineArticles whose byline prints “Ciavarella S”
  • BylineArticles whose byline prints “Scattone A”
  • BylineArticles whose byline prints “Calabrese A”
  • BylineArticles whose byline prints “Quinto AM”
  • BylineArticles whose byline prints “Guarini A”